T-cell immunity induced and reshaped by an anti-HPV immuno-oncotherapeutic lentiviral vector.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
10 Jun 2024
10 Jun 2024
Historique:
received:
30
11
2023
accepted:
23
05
2024
medline:
11
6
2024
pubmed:
11
6
2024
entrez:
10
6
2024
Statut:
epublish
Résumé
We recently developed an immuno-oncotherapy against human papillomavirus (HPV)-induced tumors based on a lentiviral vector encoding the Early E6 and E7 oncoproteins of HPV16 and HPV18 genotypes, namely "Lenti-HPV-07". The robust and long-lasting anti-tumor efficacy of Lenti-HPV-07 is dependent on CD8
Identifiants
pubmed: 38858404
doi: 10.1038/s41541-024-00894-0
pii: 10.1038/s41541-024-00894-0
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102Informations de copyright
© 2024. The Author(s).
Références
de Sanjose, S. et al. Burden of human papillomavirus (HPV)-related cancers attributable to HPVs 6/11/16/18/31/33/45/52 and 58. JNCI Cancer Spectr. 2, pky045 (2018).
pubmed: 31360870
doi: 10.1093/jncics/pky045
Zottnick, S., Voss, A. L. & Riemer, A. B. Inducing immunity where it matters: orthotopic HPV tumor models and therapeutic vaccinations. Front. Immunol. 11, 1750 (2020).
pubmed: 32922389
pmcid: 7457000
doi: 10.3389/fimmu.2020.01750
Taberna, M. et al. Human papillomavirus-related oropharyngeal cancer. Ann. Oncol. 28, 2386–2398 (2017).
pubmed: 28633362
doi: 10.1093/annonc/mdx304
Ku, M. W., Charneau, P. & Majlessi, L. Use of lentiviral vectors in vaccination. Expert Rev. Vaccines 20, 1571–1586 (2021).
pubmed: 34620025
doi: 10.1080/14760584.2021.1988854
Nemirov, K. et al. Lentiviral vectors as a vaccine platform against infectious diseases. Pharmaceutics 15, 846 (2023).
pubmed: 36986707
pmcid: 10053212
doi: 10.3390/pharmaceutics15030846
Douguet, L. et al. Full eradication of pre-clinical human papilloma virus-induced tumors by a lentiviral vaccine. EMBO Mol. Med. 15, e17723 (2023).
pubmed: 37675835
pmcid: 10565635
doi: 10.15252/emmm.202317723
Ku, M. W. et al. Lentiviral vector induces high-quality memory T cells via dendritic cells transduction. Commun. Biol. 4, 713 (2021).
pubmed: 34112936
pmcid: 8192903
doi: 10.1038/s42003-021-02251-6
Cousin, C. et al. Persistence of integrase-deficient lentiviral vectors correlates with the induction of STING-independent CD8(+) T cell responses. Cell Rep. 26, 1242–1257.e7 (2019).
pubmed: 30699352
pmcid: 6679900
doi: 10.1016/j.celrep.2019.01.025
Lopez, J. et al. A lentiviral vector encoding fusion of light invariant chain and mycobacterial antigens induces protective CD4(+) T cell immunity. Cell Rep. 40, 111142 (2022).
pubmed: 35905717
doi: 10.1016/j.celrep.2022.111142
Wang, L. et al. Hot and cold tumors: immunological features and the therapeutic strategies. MedComm 4, e343 (2023).
pubmed: 37638340
pmcid: 10458686
doi: 10.1002/mco2.343
Pinschewer, D. D. Virally vectored vaccine delivery: medical needs, mechanisms, advantages and challenges. Swiss Med. Wkly 147, w14465 (2017).
pubmed: 28804866
Saxena, M., Van, T. T. H., Baird, F. J., Coloe, P. J. & Smooker, P. M. Pre-existing immunity against vaccine vectors–friend or foe? Microbiology 159, 1–11 (2013).
pubmed: 23175507
pmcid: 3542731
doi: 10.1099/mic.0.049601-0
Martinez, I. & Wertz, G. W. Biological differences between vesicular stomatitis virus Indiana and New Jersey serotype glycoproteins: identification of amino acid residues modulating pH-dependent infectivity. J. Virol. 79, 3578–3585 (2005).
pubmed: 15731252
pmcid: 1075735
doi: 10.1128/JVI.79.6.3578-3585.2005
Fang, H. et al. Quantitative T cell repertoire analysis by deep cDNA sequencing of T cell receptor alpha and beta chains using next-generation sequencing (NGS). Oncoimmunology 3, e968467 (2014).
pubmed: 25964866
doi: 10.4161/21624011.2014.968467
Matos, T. R., de Rie, M. A. & Teunissen, M. B. M. Research techniques made simple: high-throughput sequencing of the T-cell receptor. J. Invest. Dermatol. 137, e131–e138 (2017).
pubmed: 28532760
pmcid: 5912324
doi: 10.1016/j.jid.2017.04.001
Truck, J. et al. Biological controls for standardization and interpretation of adaptive immune receptor repertoire profiling. Elife 10, e66274 (2021).
pubmed: 34037521
pmcid: 8154019
doi: 10.7554/eLife.66274
Feltkamp, M. C. et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur. J. Immunol. 23, 2242–2249 (1993).
pubmed: 7690326
doi: 10.1002/eji.1830230929
He, Y. et al. TIM-3, a promising target for cancer immunotherapy. Onco Targets Ther. 11, 7005–7009 (2018).
pubmed: 30410357
pmcid: 6198883
doi: 10.2147/OTT.S170385
Andre, P. et al. Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells. Cell 175, 1731–1743.e13 (2018).
pubmed: 30503213
pmcid: 6292840
doi: 10.1016/j.cell.2018.10.014
Wang, M. M., Coupland, S. E., Aittokallio, T. & Figueiredo, C. R. Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities. Br. J. Cancer 129, 1212–1224 (2023).
pubmed: 37454231
pmcid: 10575907
doi: 10.1038/s41416-023-02361-4
Wolf, Y., Anderson, A. C. & Kuchroo, V. K. TIM3 comes of age as an inhibitory receptor. Nat. Rev. Immunol. 20, 173–185 (2020).
pubmed: 31676858
doi: 10.1038/s41577-019-0224-6
Sakuishi, K. et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207, 2187–2194 (2010).
pubmed: 20819927
pmcid: 2947065
doi: 10.1084/jem.20100643
Heather, J. M., Ismail, M., Oakes, T. & Chain, B. High-throughput sequencing of the T-cell receptor repertoire: pitfalls and opportunities. Brief. Bioinform. 19, 554–565 (2018).
pubmed: 28077404
Bosc, N. & Lefranc, M. P. The mouse (Mus musculus) T cell receptor beta variable (TRBV), diversity (TRBD) and joining (TRBJ) genes. Exp. Clin. Immunogenet. 17, 216–228 (2000).
pubmed: 11096260
doi: 10.1159/000019141
Bosc, N. & Lefranc, M. P. The mouse (Mus musculus) T cell receptor alpha (TRA) and delta (TRD) variable genes. Dev. Comp. Immunol. 27, 465–497 (2003).
pubmed: 12697305
doi: 10.1016/S0145-305X(03)00027-2
Madi, A. et al. T-cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are associated with self-related immunity. Genome Res. 24, 1603–1612 (2014).
pubmed: 25024161
pmcid: 4199372
doi: 10.1101/gr.170753.113
Berger, B., Waterman, M. S. & Yu, Y. W. Levenshtein distance, sequence comparison and biological database search. IEEE Trans. Inf. Theory 67, 3287–3294 (2021).
pubmed: 34257466
doi: 10.1109/TIT.2020.2996543
van Montfoort, N. et al. NKG2A blockade potentiates CD8 T cell immunity induced by cancer vaccines. Cell 175, 1744–1755.e15 (2018).
pubmed: 30503208
pmcid: 6354585
doi: 10.1016/j.cell.2018.10.028
Pan, Y. G. et al. Vaccination reshapes the virus-specific T cell repertoire in unexposed adults. Immunity 54, 1245–1256.e5 (2021).
pubmed: 34004140
pmcid: 8192456
doi: 10.1016/j.immuni.2021.04.023
Tu, A. A. et al. TCR sequencing paired with massively parallel 3’ RNA-seq reveals clonotypic T cell signatures. Nat. Immunol. 20, 1692–1699 (2019).
pubmed: 31745340
pmcid: 7528220
doi: 10.1038/s41590-019-0544-5
Pogorelyy, M. V. et al. Precise tracking of vaccine-responding T cell clones reveals convergent and personalized response in identical twins. Proc. Natl Acad. Sci. USA 115, 12704–12709 (2018).
pubmed: 30459272
pmcid: 6294963
doi: 10.1073/pnas.1809642115
Klinger, M. et al. Combining next-generation sequencing and immune assays: a novel method for identification of antigen-specific T cells. PLoS ONE 8, e74231 (2013).
pubmed: 24069285
pmcid: 3778005
doi: 10.1371/journal.pone.0074231
Rojas, L. A. et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature 618, 144–150 (2023).
pubmed: 37165196
pmcid: 10171177
doi: 10.1038/s41586-023-06063-y
Acharya, N., Sabatos-Peyton, C. & Anderson, A. C. Tim-3 finds its place in the cancer immunotherapy landscape. J. Immunother. Cancer 8, e000911 (2020).
pubmed: 32601081
pmcid: 7326247
doi: 10.1136/jitc-2020-000911
Im, S. J. et al. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy. Nature 537, 417–421 (2016).
pubmed: 27501248
pmcid: 5297183
doi: 10.1038/nature19330
Gattinoni, L. et al. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat. Med. 15, 808–813 (2009).
pubmed: 19525962
pmcid: 2707501
doi: 10.1038/nm.1982
Koyama, S. et al. Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. Nat. Commun. 7, 10501 (2016).
pubmed: 26883990
pmcid: 4757784
doi: 10.1038/ncomms10501
Dixon, K. O. et al. TIM-3 restrains anti-tumour immunity by regulating inflammasome activation. Nature 595, 101–106 (2021).
pubmed: 34108686
pmcid: 8627694
doi: 10.1038/s41586-021-03626-9
Wang, X., Xiong, H. & Ning, Z. Implications of NKG2A in immunity and immune-mediated diseases. Front. Immunol. 13, 960852 (2022).
pubmed: 36032104
pmcid: 9399941
doi: 10.3389/fimmu.2022.960852
Kanevskiy, L. et al. Dimorphism of HLA-E and its disease association. Int. J. Mol. Sci. 20, 5496 (2019).
pubmed: 31690066
pmcid: 6862560
doi: 10.3390/ijms20215496
Jabri, B. et al. TCR specificity dictates CD94/NKG2A expression by human CTL. Immunity 17, 487–499 (2002).
pubmed: 12387742
doi: 10.1016/S1074-7613(02)00427-2
Welters, M. J. P., Santegoets, S. J. & van der Burg, S. H. The tumor microenvironment and immunotherapy of oropharyngeal squamous cell carcinoma. Front. Oncol. 10, 545385 (2020).
pubmed: 33425717
pmcid: 7793705
doi: 10.3389/fonc.2020.545385
Battaglia, N. G. et al. Combination of NKG2A and PD-1 blockade improves radiotherapy response in radioresistant tumors. J. Immunol. 209, 629–640 (2022).
pubmed: 35840162
doi: 10.4049/jimmunol.2100044
Iglesias, M. C. et al. A single immunization with a minute dose of a lentiviral vector-based vaccine is highly effective at eliciting protective humoral immunity against West Nile virus. J. Gene Med. 8, 265–274 (2006).
pubmed: 16308885
doi: 10.1002/jgm.837
Ku, M. W. et al. Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models. Cell Host Microbe 29, 236–249.e6 (2021).
pubmed: 33357418
doi: 10.1016/j.chom.2020.12.010
Bolotin, D. A. et al. MiXCR: software for comprehensive adaptive immunity profiling. Nat. Methods 12, 380–381 (2015).
pubmed: 25924071
doi: 10.1038/nmeth.3364
Nazarov, V. et al. Bioinformatics analysis of T-Cell and B-cell immune repertoires. immunarch https://immunarch.com/ ; https://github.com/immunomind/immunarch (2023).
Crooks, G. E., Hon, G., Chandonia, J. M. & Brenner, S. E. WebLogo: a sequence logo generator. Genome Res. 14, 1188–1190 (2004).
pubmed: 15173120
pmcid: 419797
doi: 10.1101/gr.849004